{"created":"2023-07-27T06:29:21.449940+00:00","id":14133,"links":{},"metadata":{"_buckets":{"deposit":"47a7f1b1-8f93-479a-a524-6222381512ae"},"_deposit":{"created_by":3,"id":"14133","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"14133"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00014133","sets":["1132:1133:1134"]},"author_link":["362","20454","24146","329","24147","21459","361","24145","24144","97"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-08-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"8","bibliographicPageEnd":"1419","bibliographicPageStart":"1413","bibliographicVolumeNumber":"140","bibliographic_titles":[{"bibliographic_title":"Journal of Cancer Research and Clinical Oncology"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Purpose Prostate-specific antigen (PSA) is a useful biomarker of prostate cancer (PCa). High-risk localized PCa is defined using T stage, Gleason score (GS), and PSA. However, PSA level defining high-risk PCa is at most 20 ng/mL. In PCa patients with high PSA, it is unclear whether PSA itself can be a prognostic factor. Methods Of 642 patients who were diagnosed as PCa, 90 patients with PSA > 100 ng/mL were retrospectively analyzed. Patients were divided into three groups according to PSA level: very high (>1,000 ng/mL), moderately high (200-1,000 ng/mL), and slightly high (100-200 ng/mL). Results There were no significant differences in overall survival or PCa-specific survival (PCaSS) among the three groups. Regardless of PSA level, high M stage and GS significantly reduced PCaSS. When the risk classification was made using M stage and GS (high risk = M1 and GS ≥ 9, low risk = M0 and GS < 9, and intermediate risk = others), PCaSS was significantly different among high-, intermediate-, and low-risk groups with 5-year survival rates of 58.2, 80.6, and 100 %, respectively. Although there were no differences in treatment performed during the castration-resistant stage, patients undergoing alternative anti-androgen and zoledronic acid treatment had better PCaSS after being castration-resistant. Conclusions As PSA could not be a prognostic factor in PCa patients with high PSA > 100 ng/mL, the novel risk classification using M stage and GS may help clinicians to predict PCaSS and to plan follow-up schedules after diagnosis. © 2014 Springer-Verlag Berlin Heidelberg.","subitem_description_type":"Abstract"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer-Verlag"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1007/s00432-014-1681-8","subitem_relation_type_select":"DOI"}}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AA0025708X","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0171-5216","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Izumi, Kouji"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Lin, Wen-Jye"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miyamoto, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Huang, Chiung-Kuei"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Maolake, Aerken"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kitagawa, Yasuhide"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Kadono, Yoshifumi"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Konaka, Hiroyuki"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Mizokami, Atsushi"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"Namiki, Mikio"}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-03"}],"displaytype":"detail","filename":"ME-PR-IZUMI-K-1413.pdf","filesize":[{"value":"521.8 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ME-PR-IZUMI-K-1413.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/14133/files/ME-PR-IZUMI-K-1413.pdf"},"version_id":"91471d34-052c-43fd-b116-4d81d52545e4"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level"}]},"item_type_id":"4","owner":"3","path":["1134"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-03"},"publish_date":"2017-10-03","publish_status":"0","recid":"14133","relation_version_is_last":true,"title":["Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-07-28T00:52:22.211576+00:00"}